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“Look beyond what you see” 
                                           Rafiki, ”The Lion King”  
 Prognostic impact of coronary 
microvascular function in patients with 
ischemic heart disease 
Inger Haraldsson 
Department of Molecular and Clinical Medicine, Institute of Medicine 
Sahlgrenska Academy, University of Gothenburg 
Gothenburg, Sweden 
ABSTRACT 
Background: Ischemic heart disease is the leading cause of death globally. 
Despite recent advances in interventional and medical therapies, survivors of 
myocardial infarction are at high risk of recurrent cardiovascular events. In 
recent years, coronary microvascular function has attracted more attention as 
the main target for risk stratification and as a possible target for 
pharmacological intervention as a part of multifaceted treatment of ischemic 
heart disease. Coronary flow reserve (CFR) is one of the central indices that 
reflex the status of coronary circulatory function. 
Aims: To investigate if transthoracic Doppler echocardiography-CFR (TDE-
CFR) can predict significant epicardial coronary artery stenosis (paper I); to 
investigate the prevalence of reduced CFR in high-risk patients with prior 
myocardial infarction (paper IV). To investigate the impact of thrombus 
aspiration (paper II) and pretreatment with P2Y12 inhibitors (paper III) on 
mortality in patients with STEMI undergoing PCI.  
Methods: The SCAAR registry was used for data analysis and patient 
recruitment. CFR was assessed with TDE-CFR in paper I and IV. Regression 
modelling was used for statistical analysis of data including propensity score 
adjusted logistic regression (paper I), instrumental variable analysis (paper II), 
propensity-score adjusted mixed-effects logistic regression (paper III) and 
multiple linear regression (paper IV). 
Results: TDE-CFR predicts significant coronary artery disease (paper I). 
Thrombus aspiration was not associated with any effect on mortality or stroke 
but was associated with decreased risk of stent thrombosis (paper II). 
Pretreatment with P2Y12 receptor antagonists was not associated with reduced 
IRA occlusion at the time of primary PCI or decreased stent thrombosis or 
improved survival at 30 days (paper III). Impairment of CFR was frequent in 
a high-risk post infarction population with nearly 40% of patients having 
CFR<2.5. Incomplete revascularization was the strongest independent 
predictor of lower CFR (paper IV).  
Conclusions: A majority of high-risk patients with previous MI have 
decreased CFR despite receiving adequate pharmacological treatment as a part 
of secondary prevention. TDE-CFR is a valuable tool for risk stratification in 
patients with established ischemic heart disease. High-quality observational 
studies based on large-scale registries and adequate statistical modelling 
provide valuable complementary evidence for the external validity of 
randomized controlled trials. 
Keywords: coronary microvascular function, coronary flow reserve, coronary artery 
disease, acute coronary syndromes, thrombus aspiration, pre-treatment, SCAAR, 
SWEDEHEART. 
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 SAMMANFATTNING PÅ SVENSKA 
Ischemisk hjärtsjukdom är den vanligaste dödsorsaken i världen. Individer som 
överlevt en hjärtinfarkt löper stor risk att drabbas av nya hjärthändelser trots 
dagens avancerade behandlingsformer. Hjärtats mikrocirkulation har under 
senare år visat sig spela en central roll i utvecklingen av kranskärlssjukdom 
och värdering av mikrovaskulär funktion har fått allt större intresse vid 
riskstratifiering och behandling av patienter med kranskärlssjukdom. 
Coronarflödesreserv (CFR) är ett mått på hjärtats förmåga att reglera 
blodflödet efter behov. Störd CFR har visats vara associerat med sämre 
prognos. 
Avhandlingens syften var att undersöka om CFR mätt icke-invasivt med 
ultraljud kan prediktera förekomst av signifikanta stenoser i kranskärlen 
(delarbete I), att undersöka prevalensen av nedsatt CFR hos högrisk-patienter 
med känd kranskärlssjukdom (delarbete IV), att undersöka den prognostiska 
betydelsen av att manuell trombaspiration (delarbete II) och förbehandling 
med blodplättshämmande medicin, P2Y12 hämmare, (delarbete III) hos 
patienter med ST-höjningsinfarkt som behandlas med ballongdilatation och 
stentinläggning i hjärtats kranskärl. 
Det nationella kvalitetsregistret SWEDEHEART, inkluderande Riks-HIA och 
SCAAR användes för datainsamling i samtliga delarbeten. CFR mättes med 
transthorakal ultraljudsteknik i delarbete I och IV.  
Vi fann att CFR predikterar förekomst av signifikanta stenoser på 
kranskärlsröntgen(delarbete I), att varken trombaspiration(delarbete II) eller 
förbehandling med P2Y12 hämmare(delarbete III) leder till minskad mortalitet 
efter hjärtinfarkt, att nedsatt CFR förekom hos fler än hälften av patienterna i 
en högrisk-population med känd kranskärlssjukdom(delarbete IV). 
Sammanfattningsvis, trots optimal behandling efter hjärtinfarkt har en 
majoritet av patienterna nedsatt CFR. CFR-mätning med ultraljuds-teknik är 
ett värdefullt instrument i riskstratifiering och behandling av patienter med 
kranskärlssjukdom. Observationella studier baserade på patientregister är 
viktiga komplement för att bekräfta och utvärdera generaliserbarheten av 
resultaten i randomiserade studier.
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ABBREVIATIONS 
ACS Acute coronary syndrome 
AMI Acute myocardial infarction 
CAD Coronary artery disease 
CFR Coronary flow reserve 
FFR Fractional flow reserve 
IMR Index of myocardial resistance 
IRA Infarct related artery 
LAD Left anterior descending artery 
LCX Left circumflex artery 
LDL Low density lipoproteins 
MRI Magnetic resonance imaging 
NO Nitric oxide 
PCI Percutaneous coronary interventions 
PET Positron emission tomography 
RCA Right circumflex artery 
SCAAR Swedish Coronary Angiography and Angioplasty 
Registry 
SPECT Single photon emission tomography 
STEMI ST-segment elevation myocardial infarction 
SWEDEHEART The Swedish Web-system for Enhancement and 
Development of Evidence-based care in Heart disease 
Evaluated According to Recommended Therapies 
TDE Transthoracic Doppler Echocardiography 
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INTRODUCTION 
Cardiovascular disease is the leading cause of premature adult mortality 
worldwide where acute myocardial infarction (AMI) alone stands for the 
majority of all deaths. Despite highly advanced technologies in 
revascularization and the most recently available secondary prevention 
therapies, the risk of recurrent cardiovascular events remains high at 30% in 
the first 12 month after an acute coronary syndrome1, 2. For long, clinical 
management has been centered on identification and treatment of focal 
epicardial obstructive disease. This approach is comprehensible as it is the 
epicardial part of coronary circulation that can be visualized by coronary 
angiography and is accessible to revascularization procedures. However, 
stenting or by-pass grafting of a stenosis does not address fully the underlying 
pathological mechanisms. Over the last decades, the focus has shifted away 
from obstructive epicardial coronary atherosclerosis to become centered on 
coronary microvascular function instead. Since atherosclerosis is associated 
with microvascular dysfunction which may precede development of 
atherosclerotic plaques in epicardial vessels, it is reasonable that diagnosis and 
treatment of ischemic heart disease includes microvasculature and its function.  
Coronary circulation 
Structure and function of the coronary circulation 
The coronary arteries originate from the aortic root and initially wrap around 
the outer surface of the heart (epicardial arteries) before penetrating into the 
myocardium (intramural arteries). The epicardial arteries can be visualized on 
coronary angiogram but constitutes only approximately 5-15% of the total 
coronary circulation. The remaining part of the coronary circulation, the 
microvasculature, is beyond what you see (Fig.1).  
There are some unique aspects of coronary circulation as compared to skeletal 
muscle. Energy production in the healthy heart is primarily dependent on 
oxidative phosphorylation, less than 5% of ATP-production result from 
glycolytic metabolism. This dependency on oxidative energy production 
means that any increase in cardiac activity demands an almost instantaneous  
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parallel increase of oxygen availability. As the heart has to maintain a heart 
rate of 60-70 beats per minute even at rest, oxygen consumption in the left  
ventricle during resting conditions is high, about 20-fold that of skeletal  
muscle. In order to meet this high resting oxygen demand the left ventricle has 
a high level of oxygen extraction, 70-80%, in contrast to 30-40% oxygen 
extraction in skeletal muscle. This is also in contrast to the right ventricle which 
is more similar to skeletal muscle. Oxygen extraction in the heart is facilitated 
by a high capillary-to-myocyte ratio which enables adequate exchange of 
oxygen and metabolic vast-products. Since oxygen extraction is high already 
at rest the primary mean of meeting an increased oxygen demand is to increase 
coronary flow and consequently coronary flow is strongly correlated with 
myocardial oxygen consumption3.   
 
Regulation of coronary flow 
Coronary flow is driven by the pressure difference between the aorta and the 
capillary bed. Epicardial coronary arteries without obstructive disease have a 
low vascular resistance and function mainly as conductance vessels. 
Capillaries and venules are primarily capacitance vessels, holding about 90% 
of coronary blood volume, and offer very little resistance. Most of coronary 
vascular resistance is met at the level of the pre-arterioles (epicardial vessels < 
Figure 1. The coronary angiogram reveals the epicardial arteries (A), but those constitute 
only approximately 5-15% of the total coronary circulation. The remaining part, the 
microvasculature (B) cannot be visualized. 
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500 µm in diameter) and arterioles (intramural vessels < 200 µm) which makes 
this the primary site for regulation of coronary blood flow. By alterations in 
vascular tone, resistance is changed to modulate blood flow in response to 
variations in oxygen demand.  
There are different main physiological mechanisms controlling vasomotion at 
different levels of the microcirculation. The vaso-reactivity of pre-arterioles 
(200-500 µm in diameter) and large arterioles (100-200 µm in diameter) is 
mainly endothelial-dependent and responds to changes in flow and shear stress. 
Arterioles (<100 µm in diameter), on the other hand, are mainly endothelium-
independent where medium-sized arterioles (40–100 µm in diameter) are 
under myogenic control, i.e. stretch receptors located in vascular smooth 
muscle cells reacts to changes in intraluminal pressure4, while small arterioles 
(<40 µm in diameter) respond to metabolic activity of the myocardium.  
So, in response to an increased metabolic demand the smaller arterioles dilate, 
which leads to reduced intraluminal pressure with myogenic vasodilation of 
medium-sized arterioles as a result. The following increase in upstream flow 
stimulates endothelium-dependent vasodilation at the level of pre-arterioles 
and arterioles5, 6. Coronary flow is further influenced by circulating 
neurohormones and autonomic innervation, as well as by extravascular 
compressive forces, e.g. left ventricle wall hypertrophy and hypertension 
(Fig.2). 
Figure 2. The microcirculation is the primary site for regulation of coronary flow. Different 
physiological mechanisms control vasomotion at different levels of the microcirculation. 
Adapted from Herrmann et al., European Heart Journal 2012. 
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Endothelial function and dysfunction 
Since the pioneering work of Furchgott and Zawadzki in the early 1980’s the 
endothelium is recognized as an important multifunctional regulatory organ 
involved not only in vasomotion but also in maintaining homeostasis 7-12. 
Despite being only a thin monolayer structure that separates circulating blood 
from surrounding tissue, the endothelium is the largest organ in the body as it 
covers the inner surface of the entire vascular system. Endothelial cells have 
the ability to respond to physical, chemical and humoral stimuli by production 
of both agonistic and antagonistic substances that regulate vascular tone, 
hemostasis, cellular proliferation, adhesion to the luminal surface as well as 
inflammatory and immune mechanisms in the vascular wall. 13  Nitric oxide 
(NO) is a pivotal endothelium-derived substance and mediates endothelium-
dependent vasodilation by opposing the effects of endothelium-derived 
vasoconstrictors such as angiotensin II and endothelin. Nitric oxide also 
inhibits platelet adherence and aggregation, adhesion/infiltration of leucocytes, 
and vascular smooth cell proliferation. Furthermore, nitric oxide prevents 
oxidative modification of low-density lipoproteins (LDL). Thus, the normal 
healthy endothelium is “quiescent” and maintains a relaxed vascular tone and 
low levels of oxidative stress, expressing a phenotype with anti-coagulant, 
anti-thrombotic, anti-proliferative, fibrinolytic as well as anti-inflammatory 
properties. Conversely, activation of the endothelium leads to morphologic and 
functional changes characterized by a reduction in NO, prostacyclin, and tissue 
plasminogen activator, thereby contributing to vasoconstriction mediated by 
endothelin, serotonin, and thrombin, and the endothelium is turned into a 
phenotype that is vaso-constrictive, pro-coagulant, pro-thrombotic, 
proliferative and pro-inflammatory (Fig.3).  
Activation of the endothelium is initially a host-defense response triggered by 
vascular injury or by cytokines but prolonged activation will turn the 
endothelium into a dysfunctional state prone to development of 
atherosclerosis. All traditional cardiovascular risk factors including smoking, 
aging, hypercholesterolemia, hypertension, hyperglycemia, and a family 
history of premature atherosclerotic disease are associated with endothelial 
dysfunction14-19.  Endothelial dysfunction has also been associated with 
obesity, elevated C-reactive protein, and chronic systemic infection20, 21. It is 
generally accepted that endothelial dysfunction precedes development of 
atherosclerosis22 and that endothelial function can be used as a risk marker of 
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atherosclerotic disease23. However, it is not the disturbed regulatory function 
in itself that is important. Instead, the functionality of coronary circulation  
should be seen as a marker of the pro-atherosclerotic properties of the 
circulatory system.  
Coronary artery disease 
Atherosclerosis 
Atherosclerosis is a chronic multifocal immuno-inflammatory disease of the 
arteries. The atherosclerotic process begins in early teenage years and 
continues throughout life. It is characterized by accumulation of cholesterol, 
infiltration of macrophages, proliferation of smooth muscle cells (SMC) and 
accumulation of connective tissue components in the intima of the vessel wall. 
The process of atherosclerosis has been reviewed several times22, 24 and can be 
briefly summarized as follows. The earliest event in atherosclerosis is believed 
to be injury to the endothelium which leads to endothelial activation. The 
Figure 3. The normal healthy endothelium is “quiescent” and maintains a relaxed vascular 
tone and low levels of oxidative stress, expressing a phenotype with anti-coagulant, anti-
thrombotic, anti-proliferative, fibrinolytic as well as anti-inflammatory properties. 
The activated endothelium is turned into a dysfunctional state expressing vasoconstrictive, 
pro-coagulant, pro-thrombotic, proliferative and pro-inflammatory characteristics. 
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activated endothelium triggers monocyte adhesion, loosening of endothelial 
cell junctions and migration of monocytes into the sub-endothelial space where 
monocytes differentiate to macrophages. The increased endothelial 
permeability permits LDL to enter the intima where macrophages engulf the 
LDL-particles by phagocytosis. Lipid-laden macrophages are referred to as 
“foam cells” and collections of these foam-cells form the initial lesion in 
atherosclerosis, i.e. fatty streaks. Once in the intima the LDL-particles get 
oxidized. Macrophages stimulate further oxidation of LDL and oxidized LDL 
trigger continued recruitment of monocytes into the intima. Oxidized LDL also 
inhibits nitric oxide synthase with enhanced endothelial dysfunction as a result, 
and increases generation of reactive oxygen species (ROS) i.e. free radical 
formation (superoxide, hydrogen peroxide). Oxidative stress increases 
vascular endothelial permeability and promotes leukocyte adhesion25. Other 
inflammatory cells, T-cells, are also recruited into the intima. T-cells secrete 
cytokines that trigger smooth muscle cells to migrate from the media to the 
intima. Under the influence of growth factors these smooth muscle cells begin 
to proliferate. Over time the initial lesion in atherosclerosis, the fatty streak, 
evolves to a sub-endothelial fibrous plaque composed of a lipid core 
surrounded by smooth muscle cells and connective tissue fibers, characterized 
by inflammation and high oxidative stress, a fibro-atheroma (Fig.4).   
Figure 4. The process of atherosclerotic plaque development. Adapted with permission 
from Int J Prev Med. 
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As the process advances, the fibrous cap becomes thin and weakened at sites 
where proteolytic activity dissolves the fibrous tissue. Those thin-cap fibro-
atheromas are termed vulnerable plaques as they are prone to rupture. 
Exposure of the thrombogenic interior arterial wall to the circulating blood 
initiate platelet aggregation and coagulation in the infiltrating and overlying 
blood with thrombus formation and potential occlusion of the vessel lumen as 
a consequence.  
The process of plaque development throughout life is the same independently 
of race, sex or geographic location. However, this process of atherosclerosis is 
dynamic since the presence of risk factors such as tobacco smoking, 
hypertension, obesity, diabetes mellitus and genetic predisposition, can 
accelerate the rate of plaque development. Conversely, reducing the 
cardiovascular risk burden may probably slow down the process since early 
stage lesions, fatty streaks, may regress and many ruptures of thin fibrous caps 
remain clinically silent as they have the potential to heal by forming new 
fibrous tissue.  
Clinical manifestations of coronary artery disease 
As the fibroatheroma grows, the arterial wall enlarges its caliber trying to avoid 
reduction of lumen by the plaque. This remodeling of the vessel is stopped 
when the plaque engages about 40% of the area of the artery. Any further 
plaque enlargement reduces vessel lumen and when blood flow is insufficient 
to meet the metabolic demand the plaque has become a hemodynamically 
significant stenosis, which causes ischemia. This is typically the situation in 
stable angina pectoris where initially a more extensive work load is needed to 
provoke ischemia and symptoms of angina but with increasing severity of the 
stenosis lower grades of exertion, or even no physical stress, may elicit 
symptoms. While a reduction of vessel lumen of 50% is hemodynamically 
significant at stress, a narrowing of >85% is demanded to elicit ischemia at 
rest26. Acute coronary syndromes(ACS) are predominantly characterized by 
acute thrombus formation causing partial or total arterial occlusion with 
subsequent myocardial ischemia and potential death of cardiomyocytes. ACS 
manifest as ST-elevation myocardial infarction (STEMI) in the case of total 
vessel occlusion and as non-STEMI or unstable angina in subtotal occlusions 
(Fig.5).  
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In post-mortem studies on patients with ACS and sudden death, thrombosis is 
found to be due to rupture of thin cap fibroatheroma in approximately 50-60% 
of cases, erosion of the endothelium in 20% and in rare cases, 2%, thrombosis 
is due to protrusion of a calcified nodule into vessel lumen. Interestingly, in 
20-30% of ACS and sudden cardiac death, there is an advanced stenosis but 
thrombus formation is abscent27. Notably, up to one-third of patients with 
symptoms suggestive of ACS and raised levels of troponins and/or ischemic 
changes on ECG, have normal or near-normal arteries on coronary 
angiography28, 29. Likewise, 10-30% of patients referred to elective coronary 
angiography due to chest pain have coronary arteries without obstructive 
epicardial disease30. As many as 50-60% of these patients have reduced CFR 
due to coronary microvascular dysfunction. This condition is 
termed microvascular angina (MVA)31-33. 
Treatment of coronary artery disease 
The primary goal in acute coronary syndromes is to minimize ischemia and 
myocardial injury due to thrombus formation with subsequent total or sub-total 
obstruction of the coronary vessel. An urgent reperfusion strategy is needed in 
the case of STEMI and percutaneous coronary intervention (PCI) is generally 
the first choice. Pharmacological reperfusion (thrombolysis) is recommended 
Figure 5. Pathogenesis and clinical manifestations of coronary artery disease. Adapted from 
Libby P. Circulation. 2001. 
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as an alternative in the case of short duration of symptoms and if transport time 
to nearest catheterization-laboratory is expected to be long (>120 minutes 
according to current guidelines). In some settings revascularization with 
coronary artery by-pass grafting (CABG) is the preferred strategy. 
Antithrombotic therapy in the acute phase, with aspirin and low-weight 
molecular heparins, aims at limiting the size of the thrombus in the coronary 
artery and to prevent continued thrombus organization. In 1967 the mechanism 
of action of aspirin (acetylsalicylic acid) on platelet activity was discovered34 
and later the clinical benefit of aspirin on vascular death, non-fatal MI and 
stroke has been demonstrated in patients at high risk of serious cardiovascular 
events35, 36. Addition of a P2Y12-inhibitor to aspirin (i.e. dual antiplatelet 
therapy) has been shown to reduce acute ischemic complications, recurrent 
athero-thrombotic events and stent thrombosis after PCI37. There are currently 
three classes of antiplatelet agents approved for clinical use in patients with 
ACS or in patients undergoing PCI; cyclooxygenase-1 (COX-1) inhibitors 
(aspirin), adenosine diphosphate (ADP) P2Y12 receptor antagonists 
(ticlopidine, clopidogrel, prasugrel, ticagrelor), and glycoprotein IIb/IIIa 
inhibitors (abciximab, eptifibatide, tirofiban). The use of the first P2Y12-
inhibitor, ticlopidine, was limited by frequent side effects, including severe 
neutropenia and thrombotic thrombocytopenic purpura (TTP), and ticlopidine 
was soon replaced by clopidogrel since clopidogrel had a better safety profile 
and a faster onset of action. The benefit of adding clopidogrel to aspirin to 
prevent recurrent cardiovascular events has been demonstrated in several 
trials38-40 and dual antiplatelet therapy with aspirin and clopidogrel has been 
standard care for more than a decay. Recently, the more potent P2Y12-
inhibitors, prasugrel and ticagrelor, have been proven superior compared to 
clopidogrel in reducing major adverse cardiovascular outcomes although both 
ticagrelor and prasugrel substantially increase the risk of bleeding41, 42.  
Long-term treatment of ischemic heart disease aims at preventing future 
cardiovascular events such as recurrent ACS, arrhythmias, heart failure and 
sudden cardiac death. Established medical treatment with prognostic value 
include beta-blockers43, ace-inhibitors(ACE-I)44 and statins45 on top of dual 
antiplatelet therapy39. The mechanisms of action for all these therapies are 
multifaceted and many of them affect microvascular function at some level and 
are proved to improve endothelial function46, 47.  
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An important part of secondary prevention consists of lifestyle changes such 
as smoking cessation, increased physical activity, stress management, dietary 
changes and participation in rehabilitation programs48.    
Coronary flow reserve 
Coronary flow reserve (CFR) is the ability of the heart to increase coronary 
flow in response to an increased myocardial oxygen demand and is defined as 
the ratio of maximum coronary flow to coronary flow at rest. The concept of 
coronary flow reserve was first established by Gould et al. in 197426 when they 
demonstrated a relationship between severity of coronary stenosis and 
hyperemic coronary flow response. With increasing restriction of a coronary 
artery, resting flow initially remains unchanged, while maximum coronary 
flow decreases gradually and a completely abolished flow is found for stenosis 
>90%. However, coronary anatomy is not the lone determinant of the reserve 
capacity of coronary flow. CFR is the net result of all the complex mechanisms 
involved in regulation of coronary blood flow. As a consequence, CFR reflects 
both endothelial-dependent and -independent microvascular function, as well 
as flow-limiting epicardial disease and rheological properties of circulating 
blood. The normal healthy heart can increase coronary blood flow 3-6 times 
the resting value (Fig.6). 
Figure 6. CFR mirrors all complex mechanisms involved in regulation of coronary flow. 
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Methods to assess coronary flow reserve 
Several imaging modalities have been used to assess the functionality of 
coronary circulation. In most clinical applications, hyperemia is induced 
pharmacologically, commonly with agents such as adenosine and 
dipyridamole, and not via an increase in oxygen demand. Adenosine and 
dipyridamole act mainly by a direct relaxing effect on vascular smooth 
muscle cells with non-endothelial-dependent vasodilation as the primary 
effect, followed by a secondary flow-mediated endothelial-dependent 
response. In some settings cold-pressure test is used to specifically evaluate 
direct endothelial-dependent coronary vasomotion. Several factors influence 
measurement of CFR, e.g. the ability to achieve maximal coronary 
vasodilation, heart rate, myocardial contractility and right atrial pressure. 
These factors have different impact depending on the method used for 
evaluation of CFR and must be kept in mind at interpretation of the results. All 
methods have their technical advantages as well as disadvantages, and also 
differ when it comes to costs and availability.  
The earliest CFR-measurements were invasive with the use of an 
intracoronary Doppler flow wire. Doppler flow wires make it possible to 
calculate coronary flow velocity reserve (CFVR) by dividing intracoronary 
mean velocity at pharmacologically induced hyperemia with baseline mean 
velocity at rest. As long as vessel lumen area is kept constant, which is a 
reasonable assumption with drugs such as adenosine and dipyridamole, blood 
velocity is proportional to flow and CFVR can be approximated to CFR49, 50.  
Intracoronary Doppler has for long been the gold standard for invasive 
assessment of CFR but currently thermodilution-techniques, with the use of 
pressure-temperature sensor-tipped guidewires, are more common. Transit 
times for manual injections of saline at room temperature at rest and during 
hyperemia induced by intravenous adenosine are used to calculate CFR. 51, 
52.  The same pressure guidewire can be used to assess myocardial fractional 
flow reserve (FFR) and for calculation of the index of myocardial resistance 
(IMR). FFR is defined as the resting distal coronary pressure to aortic pressure 
ratio (Pd/Pa) during hyperemia. When coronary resistance is minimized, as it 
is assumed to be during hyperemia, flow is linearly related to blood pressure 
and FFR becomes a surrogate measure of flow limitation and an index of 
coronary stenosis severity and ischemia53. FFR is independent of baseline flow 
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and heart rate and is easy to perform to the experienced operator. However, a 
good understanding of the methodology is required to get optimal data and for 
correct interpretation. In the “DEFER” study it was shown to be safe to defer 
patients with one-vessel stable CAD and FFR>0.7554. In the “FAME” trial on 
patients with multivessel CAD, FFR<0.80 was shown to be a physiological 
threshold indicating ischemic obstructive coronary disease that could benefit 
from revascularization55.  In the “COMPARE ACUTE” trial on patients with 
STEMI and multivessel disease, Smits et al. showed that FFR-guided 
revascularization of non-culprit lesions had a 65% reduced risk of MACCE 
(death from any cause, nonfatal myocardial infarction, revascularization, and 
cerebrovascular events) at one year (HR 0.35; 95% CI, 0.21-0.58; P<0.001) 
compared to STEMI-patients with PCI of the infarct-related artery only56. 
Measurement of FFR for functional lesion assessment in CAD is now 
recommended in guidelines from American College of Cardiology 
(ACC)/American Heart Association (AHA) and the European Society of 
Cardiology (ECS)/European Association of Cardio-Thoracic Surgery 
(EACTS) 57-59.  
Another rather novel but interesting measure, derived from the pressure-wire, 
is the index of myocardial resistance (IMR). Coronary microcirculation is the 
main determinant of myocardial resistance and assessment of myocardial 
resistance will provide information on microvascular function. Assuming that 
coronary flow and myocardial flow is equal and that collateral flow is 
negligible, IMR is the ratio of distal coronary pressure to coronary flow and 
can be calculated from parameters derived from the CFR-measurement60. IMR 
measurement is reproducible and independent of variations in heart rate, blood 
pressure and myocardial contractility61. So far, IMR is not generally used in 
clinical practice but has been studied in stable CAD and is found to be of 
prognostic importance in AMI62-65. Thus, the combined measures of CFR, FFR 
and IMR give lesion-specific information on epicardial level as well as 
information on microcirculatory level simultaneously (Fig.6).  
Positron Emission Tomography(PET) is considered the non-invasive gold 
standard for evaluation of quantitative regional blood flows and allows 
measurement of myocardial perfusion and function at stress and rest. Absolute 
myocardial blood flow (MBF) in milliliter/minute/gram can be quantified in 
the same study. This technique also allows calculation of coronary flow reserve 
(CFR) or myocardial flow reserve (MFR)66. Recent studies have shown that 
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measurements of CFR assessed by PET can provide important prognostic 
information over semi-quantitative perfusion data67. It is an appealing 
technique through its non-invasive nature but it is expensive and at present 
only available at a limited number of institutions.  
Single Photon Emission Computed Tomography (SPECT), is another 
commonly used non-invasive technique to assess relative myocardial perfusion 
but can also get quantitative measurements of myocardial perfusion and 
perfusion reserve. After intravenous administration of a radionuclide tracer 
estimates of global and regional myocardial perfusion reserve can be 
calculated by dividing perfusion values at stress with values at rest. CFR-
values estimated by SPECT imaging are well correlated to intravascular 
Doppler ultrasound-derived CFR68and has also been validated by comparisons 
with PET imaging69.  
Cardiovascular magnetic resonance imaging (CMRI) is a technique that has 
developed rapidly the last fifteen years. CMRI is used to study myocardial 
structure, cardiac function, macro vascular blood flow, myocardial perfusion 
and myocardial viability. Key advantages are the non-invasive nature, no 
ionizing radiation and good image quality. Disadvantages on the other hand, 
are limited availability, expense and special technical training of those who 
perform CMRI.  
Recent years, evolution of echocardiography-based techniques used to assess 
coronary flow velocities, have been recognized as a valuable tool in evaluation 
of CFR. Initially, measurements of coronary flow velocities were semi-
invasive recorded with a trans-esophageal doppler technique. Development of 
technological factors, such as second harmonic imaging and high-frequency 
transducers with better definition of smaller structures and improved resolution 
imaging of near-field structures, have enabled assessment of CFR with 
transthoracic Doppler technique. Using pulsed wave Doppler 
echocardiography under the guidance of color Doppler flow mapping, 
coronary flow velocity reserve can be measured by dividing mean hyperemic 
flow velocity to mean flow velocity at rest. Assessment of CFR with 
transthoracic doppler can be performed in all three coronary arteries e.g. left 
anterior descending artery (LAD), left circumflex artery (LCX) and right 
coronary artery (RCX)70, 71. Validation of feasibility and reproducibility of the 
transthoracic Doppler technique have been described previously58, 59. Accuracy 
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of the method has also been validated against invasive techniques70. 
Transthoracic Doppler technique is patient-friendly as it is easy tolerable and 
associated with low risk, furthermore it is not expensive and easy accessible in 
all institutions.  
Cut-off values of coronary flow reserve 
There is not one single defined cut-off value of CFR. Different cut-off values 
have been proposed for diagnosis of significant epicardial coronary artery 
disease and for estimation of cardiovascular prognosis. Matsamura et al. 
measured CFR with transthoracic doppler  echocardiography (TDE-CFR) in 
138 patients with various cardiovascular risk factors undergoing coronary 
angiography, and found a best cut-off value of CFR <2.0 for detection of 
significant LAD stenosis72. A similar finding was made by Cortigiani et al who 
demonstrated a cut-off value of TDE-CFR<1.91 for detecting ≥75% stenosis 
of the left anterior descending artery (LAD) in 2089 patients with known or 
suspected CAD. This was true in both hypertensive patients (area under the 
curve 0,86) and in normotensives (area under the curve 0,90)73. Comparable 
conclusions have been reached by other groups70, 74 and a cut-off of CFR<2.0 
for detection of significant stenosis has been generally accepted.  
However, to predict a favorable cardiovascular prognosis a CFR-value>2.0 is 
not suitable. Nakanishi et al demonstrated that CFR<2.4 was the best cut-off 
value in predicting a combination of long-term cardiovascular events, acute 
coronary syndromes and the development of heart failure (area under the 
curve=0.82). CFR was an excellent predictor of heart failure development 
(area under the curve=0.95). For prediction of acute coronary syndromes the 
area under the curve was 0.6775. In this study population TDE-CFR was 
performed on 272 patients without significant obstructive CAD on 
angiograms. Similar findings have been made in patients with diabetes where 
an optimal cut-off value to predict cardiovascular events was 2.5 (area under 
the curve=0.65). The event rate was significantly higher in patents with 
CFR<2.5 than in those with CFR>2.576. In conclusion, for detection of 
significant coronary artery disease a cut-off of CFR<2.0 is accurate while the 
optimal cut-off value to predict cardiovascular events is CFR< 2.5. 
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Clinical and prognostic impact of coronary flow reserve 
In analogy with dysfunction of the endothelium, impaired CFR is associated 
with several of the established cardiovascular risk factors, e.g. age77, 78, 
obesity79, hypertension80-82, hyperlipidemia83, 84, diabetes85-87, renal 
dysfunction88, and smoking89, 90 . This has been demonstrated in patients 
without concomitant significant CAD and in this setting impaired CFR reflects 
microvascular function91. CFR can be used as an indicator summarizing 
cardiovascular risk92 and has been shown to be a strong predictor of future 
cardiovascular events including death, MI, stroke, and need for coronary 
revascularization.  
In the “DEBATE” study from 1997, CFR was measured with intra-coronary 
Doppler post-PCI and was found to have prognostic value in patients with 
myocardial infarction93. Traditionally long-term prognosis after MI is 
estimated based on TIMI-flow, age, reduced left ventricular function and 
infarct size but still accurate identification of high risk individuals in this 
patient cohort is insufficient. Interestingly, CFR is shown to give additional 
prognostic information on top of established cardiovascular risk markers in 
some recent studies. Murthy et al performed positron emission tomography 
(PET) in patients with known or suspected CAD and found that CFR was an 
independent predictor of mortality. Risk was also shown to increase with 
decreasing CFR67. In a similar patient cohort, Cortigiani et al evaluated CFR 
with transthoracic Doppler echocardiography and found a significantly higher 
4-year mortality in patients with CFR<2 compared to patients with CFR>294. 
The findings by the groups of Murthy and Cortigiani, of CFR as an additive 
prognostic marker, were independent of prevalence of ischemia measured by 
PET scan or stress-echo respectively. Transthoracic Doppler derived CFR has 
also been found to add incremental prognostic value above myocardial 
perfusion scintigraphy in patients with suspected ischemic heart disease95.  
Other studies have evaluated the prognostic impact of reduced CFR in patients 
with and without diabetes as well as in patients with renal insufficiency. Both 
diabetes mellitus and chronic renal dysfunction are in themselves associated 
with increased cardiovascular risk. Diabetic patients without known CAD had 
similar rates of cardiac mortality as non-diabetics with known CAD. 
Conversely, diabetics without known CAD and without CFR-impairment had 
rates of cardiac death that were comparable to nondiabetics96, 97. Likewise, in 
patients with chronic renal dysfunction evaluation of CFR improved risk 
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stratification beyond routine measures of risk such as left ventricular systolic 
function and severity of myocardial ischemia and infarct size98.  
Prognostic impact of impaired CFR has also been observed in several other 
pathological conditions such as non-ischemic cardiomyopathies99, 100, 
transplant vasculopathy101 as well as in aortic valve disease102.Thus, there are 
substantial evidence for the correlation between impaired CFR and 
cardiovascular risk factors and the prognostic value of CFR on cardiac 
mortality.   
Impact of secondary prevention on coronary flow reserve 
Treatment of cardiovascular risk factors may improve CFR. In smokers, 
improvement of CFR was demonstrated after 1 month of smoking cessation103. 
In patients with hypertension and stable CAD, treatment with angiotensin 
receptor blockers (ARB) resulted in improved CFR. This improvement 
preceded the reduction of blood pressure104. Similar beneficial effects on CFR 
has been demonstrated after treatment with angiotensin converting enzyme-
inhibitors (ACE-I)105, 106 and beta-blockers107 in hypertensive patients.  Statin 
therapy also significantly improved CFR in cardiovascular risk patients with 
hypertension and average levels of serum cholesterol. The change in CFR 
correlated with a change in LDL108. Improvement of CFR has also been 
demonstrated on patients with multivessel disease treated with statins. In this 
study increased CFR was delayed compared to the lipid lowering effect of 
fluvastatin which may be suggestive of a slow recovery of the vaso-dilatory 
response109. Further, the improvement of CFR was independent of severity of 
stenosis and not related to the amount of lipid lowering effect. Treatments in 
diabetes aim at preventing the metabolic effects of high glucose levels as well 
as microvascular and macrovascular damage and associated complications. 
Intense anti-hyperglycemic treatment has been demonstrated to significantly 
improve CFR in diabetic patients with poor glycemic control 110. Physical 
activity and weight loss are also associated with improvement of CFR111-113. 
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Thrombus aspiration 
The goal of reperfusion therapy in STEMI is to limit infarct size by improving 
blood and oxygen supply to the ischemic myocardium. However, despite 
optimal restoration of epicardial coronary blood flow with PCI, myocardial 
reperfusion is still impaired in a substantial number of patients with STEMI114, 
115. One possible mechanism is distal micro embolization causing 
microvascular obstruction116 which is associated with impaired prognosis64, 117.  
An appealing approach to reduce thrombus burden and embolization to the 
microvasculature has been mechanical aspiration of thrombus before stenting 
in STEMI-PCI (Fig.7).  
Some early, smaller studies demonstrated improved microvascular function, 
reduced infarct size and increased survival in STEMI-patients treated with 
thrombectomy before PCI118-121. Though, the beneficial effects of thrombus 
aspiration on short-term and long-term mortality could not be confirmed in 
neither of the two recent large randomized controlled trials, TASTE122 
(Thrombus Aspiration in ST-Elevation Myocardial Infarction in Scandinavia) 
and TOTAL123 (The Trial of Routine Aspiration Thrombectomy With PCI 
Figure 7. Schematic illustration of manual thrombus aspiration from coronary artery.  
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Versus PCI Alone in Patients With STEMI). The TASTE study demonstrated 
a trend for reduced risk of stent thrombosis and reinfarction while the TOTAL 
study found an association between thrombus aspiration and an increased risk 
of stroke. Still, routine thrombus-aspiration in STEMI-patients is frequently 
used. 
Pretreatment in STEMI 
Antiplatelet therapy is a corner-stone in standard-care of ischemic heart 
disease. Dual antiplatelet inhibition with aspirin and a P2Y12 inhibitor is 
beneficial in reducing ischemic events even though this may be at the expenses 
of increased bleeding risk39, 41, 42. However, the timing of administration of 
P2Y12 inhibitor along with aspirin, remains uncertain.  In patients with ACS 
platelets are more activated and hyper-reactive than in patients with stable 
coronary artery disease124. Particularly in STEMI a prolonged onset of action 
of P2Y12 inhibitors has been demonstrated compared to onset-times in patents 
with stable CAD125, 126. In the light of these background facts, a strategy in 
which P2Y12 inhibitors are administered early to patients with ongoing MI is 
both logical and attractive. For many years, the European and American 
guidelines (ESC/ACC/AHA) have recommended pre-hospital administration 
of P2Y12 inhibitors to patients with ST-elevation myocardial infarction 
(STEMI) and this strategy has become a common practice 127, 128. However, the 
available evidence regarding the safety and efficacy of this strategy in the 
setting of primary PCI is conflicting128. Most data favoring prehospital 
administration of P2Y12 inhibitors do not directly address STEMI-population 
undergoing primary PCI40, 129, 130. Two smaller randomized trials of 
pretreatment in primary PCI had surrogate endpoints and were negative131, 132. 
There is only one large randomized trial in patients with STEMI that directly 
addressed the hypothesis whether prehospital administration of P2Y12 
inhibitors results in improved outcomes. In this trial the co-primary endpoints 
were the proportion of patients without a 70% or greater resolution of ST-
segment elevation before percutaneous coronary intervention (PCI) and the 
proportion of patients without Thrombolysis in Myocardial Infarction flow 
grade 3 (TIMI-3) in the infarct-related artery at initial angiography. Rates of 
major adverse cardiovascular events and stent thrombosis at 30 days were 
secondary endpoints. Beneficial effects could not be demonstrated neither on 
reperfusion indices nor on clinical outcomes133. So far, no trials investigating 
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the timing of P2Y12 inhibitors have had enough statistical power to evaluate 
mortality and complications relevant in the clinical setting. 
Statistical considerations in observational 
studies 
Properly planned and executed randomized controlled trials (RCT) are 
considered the gold standard of evidence based medicine. Random assignment 
to different treatment (i.e. exposure) makes the groups as equal as possible with 
respect to all patient characteristics that may have an impact on the outcomes 
of interest. Accordingly, the act of randomization minimizes the confounding 
in risk estimation (i.e. causation) by means of statistical models. However, 
since patients included in RCTs may be—and often are—selected due to 
specific inclusion and exclusion criteria, many RCTs have limited external 
validity. That is, patients included in RCTs are usually younger with less 
comorbidity and at lower risk of mortality (or other adverse events of clinical 
importance). The study results from such a population cannot be directly 
extrapolated to the patients that were excluded from the RCTs. Still, the 
excluded population from RCTs represent a substantial portion of patients who 
we meet in everyday clinical practice134. Within the realm of evidence-based 
medicine, high-quality observational studies based on large-scale registries and 
on accurate statistical methodology are valuable complements to RCTs. Such 
studies may provide important and valuable evidence for the external validity 
of RCTs that were previously conducted. While large-scale observational 
studies are an important tool in epidemiology and evidence-based medicine, 
they have their own limitations. As patients are not randomized to a specific 
exposure (or treatment) there will often be differences in patient’s 
characteristics between the groups of interests, which makes causation 
between exposure and outcome harder to prove because of many possible 
sources of bias many of which have been studied in detail135, 136. 
Missing data 
Missing data are common in observational studies and may lead to reduced 
representativeness of the sample. As a consequence, inferences about the 
population may be biased.  It is important to understand the reasons for missing 
to correctly deal with the remaining data. Values missing completely at random 
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are not likely to affect the representativeness of the population. But if values 
are missing systematically, analysis is likely to be biased. There are three main 
mechanisms of missing. “Missing completely at random” means that missing 
values occur entirely at random and are independent of observable as well as 
unobservable variables and analysis of remaining data will be unbiased. 
However, data are rarely “missing completely at random”. Data are 
categorized as “missing at random” if there are systematic differences between 
missing and the observed variables, as long as these differences can be entirely 
explained by other observed variables. But, if the probability of missing is 
dependent on the missing value, even after controlling for other variables, then 
data is “missing not at random”. When data are “missing not at random”, valid 
inferences require explicit assumptions about the mechanisms that led to the 
missing data. On the other hand, when missing data can be assumed to be 
“missing at random” or “missing completely at random”, then standard 
implementations of multiple imputation methodology can be used and missing 
data can be handled in a way that is unbiased and statistically valid. Methods 
dealing with “missing at random”-data are divided into three main classes; 
likelihood-based approaches, weighted estimation and multiple imputation. 
The most frequently used method is multiple imputation due to its flexibility 
especially in the case of multiple missing values137-139. General 
recommendations on how to report and handle missing data in observational 
studies are described in the document of “Strengthening the Reporting of 
Observational Studies in Epidemiology” (STROBE)140.  
Propensity score 
In observational studies, factors such as patient characteristics and treatment 
preferences of the hospital or the individual physician, often influence 
treatment selection resulting in systematic differences in baseline 
characteristics between treated and untreated subjects. This has to be accounted 
for when the effect of treatment on outcomes is estimated. Historically 
regression models have been used for adjustment of differences in measured 
baseline characteristics between treatment groups. Another way to handle this 
is to use methods based on propensity score to reduce or eliminate the effect 
of confounding. The propensity score was defined by Rosenbaum and Rubin 
in 1983, as the probability of treatment assignment conditional on observed 
baseline characteristics141. The propensity score is a balancing score since the 
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distribution of baseline characteristics will be similar between treated and 
untreated subjects, conditional on the propensity score. In RCTs, where 
treatment allocation is random, the propensity score is known and will be 0,50 
for each patient, i.e. each patient has 50 percent chance of receiving either 
treatment, independent of baseline characteristics. In observational studies the 
propensity score is unknown but can be estimated, usually with logistic 
regression adjusted for those covariates having most influence on which 
treatment the patient will be assigned to. Thus, in a set of subjects with the 
same propensity score, the distribution of observed baseline covariates will be 
the same in the treated and in the untreated group. There are four different 
propensity score methods; matching, stratification, weighting and covariate 
adjustment using the propensity score. Propensity score matching is formation 
of matched sets of treated and untreated subjects with similar propensity score 
values. Matching requires a large sample with a large overlap of propensity 
scores because those observations that cannot be matched will be excluded 
from the analysis.  Stratification is achieved by stratifying subjects into equal-
size groups based on their estimated propensity score and then entering the 
strata as covariates in the equation. In covariate adjustment the estimated 
propensity score is entered in a regression model as a continuous variable. 
Weighting is a method where weights, based on the estimated propensity score, 
are used to make a synthetic sample where the distribution of baseline 
characteristics is independent of treatment assignment. An important part of 
any propensity score analysis is balance diagnostics, i.e. examining whether 
the propensity score model has been adequately specified142. 
Multilevel models  
In many observational studies based on data from health care registries, the 
observations are organized in hierarchical manner. This means that the 
structure of the data in registries often is such that it contains two or more levels 
of data (i.e. clusters). In health care registries, patients (first level) may be 
clustered within the hospital (second level) and hospitals may be clustered 
within specific regions or different countries (third level). Sometimes the 
primary unit of observation may be other than the individual patient, for 
example, implanted coronary stents (first level) may be clustered within 
patients (second level) while patients may be clustered within hospitals (third 
level). As a consequence, observations on patients (or other clustered primary 
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observation unit) will not be independent of each other. Most of the models 
used for statistical inference assumes independency of individual observations 
from each other. Patients treated at one hospital are likely to be treated more 
similar compared to patients at another hospital. This non-independent nature 
of clustered observations may be appropriately addressed by means of 
multilevel modelling. Failure to apply proper statistical modelling for clustered 
data may result in substantially biased risk estimates and both type-1 and type-
2 error. In ordinary regression models, data are fitted to the most suitable 
parameters, i.e. intercept and slope, and the estimated value will be a straight 
line with a certain intercept and a certain slope. In multilevel models each level 
will have its own regression line and depending on the nature of data 
parameters can be fixed, i.e. constant over all groups, or random, i.e. values 
will be different for each group. Thus, multilevel models can have random 
intercepts and fixed slopes or vice versa, or both random intercepts as well as 
random slopes. 
Instrumental variable analysis 
Confounding in observational studies can be partly handled with multivariate 
adjusted regression analysis and propensity score methods, as long as 
confounders are known and measured. Still, the problem with unmeasured 
and/or unknown confounders causing potential endogeneity remains and 
makes it difficult to prove causation when estimating the effect of a 
treatment143. Variables are endogenous when they are correlated with other 
variables and the error term in the regression model. Endogenous correlation 
may occur when changes in the outcome changes the value of one or more of 
the covariates (“reverse” causation), when there are variables that affect both 
the outcome and the independent variables or when there are measurement 
errors. Instrumental variable procedures can be used to reduce bias in the case 
of endogenous correlation144, 145. To use instrumental variable analysis, one 
must identify a naturally varying phenomenon in the observed data, which like 
the act of randomization in an RCT, predicts the treatment that will be assigned 
to the individual patient. To become a valid instrument, a variable has to fulfill 
some necessary criteria. First, it has to be strongly associated with the received 
treatment. Second, it must not be associated neither directly nor indirectly with 
the outcome, except through the effect of the treatment itself. The variable with 
these statistical qualities is called instrumental variable, or instrument. 
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Commonly, geographic location is used as an instrument e.g. health care 
regions or different countries. The estimate of an instrumental variable analysis 
is predominantly determined by subgroups, whose treatment status depends on 
which category of the instrument the patient belongs to, e.g. patients with the 
same characteristics receiving different treatments in different geographical 
regions. The most commonly used technique for instrumental variable analysis 
is the 2-stage least squares method (2SLS). In the setting of dichotomous 
exposures and outcomes, 2SLS produces a risk difference estimate146. This 
procedure works by sequential application of 2 ordinary least squares 
regressions in which predicted values of treatment from the first stage are 
entered into the second stage as a replacement for actual treatment. By 
replacing the confounded treatment variable with an unconfounded prediction 
of treatment, the bias due to unmeasured confounding can be avoided. 
The SCAAR/SWEDEHEART registries 
The Swedish Web-system for Enhancement and Development of Evidence-
based care in Heart disease Evaluated According to Recommended Therapies 
(SWEDEHEART) was established in December 2009 after merging of four 
existing national registries namely the registry of acute cardiac care (RIKS-
HIA), the Swedish coronary angiography and angioplasty registry (SCAAR), 
the Swedish heart surgery registry and the national registry of secondary 
prevention (SEPHIA). RIKS-HIA was established as a National quality 
registry in 1995. SCAAR was established in 1999 after a merge of the Swedish 
Coronary Angiography registry (Acta Coronaria) and the Swedish Coronary 
Angioplasty registry (SCAP) both initiated in the early 1990s by hospitals 
which at that time performed coronary angiographies and PCIs. The Swedish 
heart surgery registry was formed in 1992 and SEPHIA was added to RIKS-
HIA in 2005 to register effects of secondary prevention efforts in patients with 
acute myocardial infarction147. The Registry for Percutaneous Valve 
Interventions was incorporated in SWEDEHEART in 2010. SWEDEHEART 
is a national registry including all patients admitted to hospital due to suspected 
ACS and patients undergoing coronary or valvular interventions.  
Approximately 80,000 cases are enrolled each year: 30,000 with ACS, 40,000 
undergoing coronary angiography or angioplasty, 7,000 undergoing heart 
surgery, and 6,000 who are followed for 12–14 months for secondary 
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prevention after ACS. The registry is web-based and all data are registered on-
line directly by the caregiver and transferred in an encrypted format to a central 
server. The platform is in direct contact with the Swedish National Population 
Registry for immediate access to personal data and deaths. The technology is 
developed and administered by Uppsala Clinical Research Center (UCR). 
SWEDEHEART, including SCAAR, is independent of commercial funding 
and is sponsored by Swedish health authorities only.  
For patients admitted to hospital due to symptoms suggestive of ACS, 106 
variables are collected prospectively including patient demographics, logistics 
at admission, risk factors, past medical history, medical treatment prior to 
admission, electrocardiographic changes, biochemical markers, other clinical 
features and investigations, medical treatment in hospital, interventions, 
hospital outcome, discharge diagnoses and discharge-medications.  
In SCAAR each angiography procedure is described with ~50 variables and 
each PCI procedure with ~200 variables including detailed descriptions of 
angiographic findings, procedures, type of stenosis, type of stent, 
antithrombotic treatment, and complications. The system presents detailed 
information about every previously implanted stent anywhere in the country 
and a question about existence of any form of restenosis or stent thrombosis is 
Figure 8 Schematic illustration of organization of the SWEDEHEART registry (The 
Swedish Web-system for Enhancement and Development of Evidence-based care in 
Heart disease Evaluated According to Recommended Therapies). 
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mandatory. The information about clinical characteristics and procedural 
details is entered into the registry immediately after the procedure by the PCI 
physician. Data on in-hospital complications, e.g. bleeding and neurological 
complications, is entered into the registry at discharge, according to local 
routines at each hospital.  
Swedish personal identification numbers together with name, address and 
hospital are included in the registry. The SWEDEHEART database is merged 
with the National Cause of Death Register, which includes information about 
the vital status of all Swedish citizens, and the National Patient Registry, which 
includes diagnoses at discharge for all hospital stays in Sweden. The merging 
of the registries is approved by the National Board of Health and Welfare, the 
Swedish Data Inspection Board, and the ethical committee at Uppsala 
University. All patients are informed about their participation and follow-up in 
the registry and have the right to decline inclusion. The registry captures 100% 
of the patients undergoing angiography, angioplasty or heart surgery and 
approximately 90% of patients admitted to hospital due to symptoms 
suggestive of ACS. 
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AIMS 
The specific aims of this thesis were as follows; 
I: To investigate if TDE-CFR can predict significant epicardial coronary artery 
stenosis in patients with symptoms of angina. 
II: To investigate the impact of thrombus aspiration on mortality, stent 
thrombosis and stroke or neurologic complications in patients with STEMI 
undergoing PCI. 
III: To investigate the impact of pre-hospital administration of P2Y12 
antagonists on mortality, infarct-related artery occlusion (IRA), stent 
thrombosis, cardiogenic shock, bleeding, and neurological complications in 
patients with STEMI undergoing PCI. 
IV: To investigate the prevalence of reduced TDE-CFR and to find 
independent predictors of reduced TDE-CFR in cardiovascular high-risk 
patients with prior myocardial infarction.  
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PATIENTS AND METHODS 
Data from the prospective SCAAR (Swedish Coronary Angiography and 
Angioplasty Registry) database were used in all four papers. In paper I and IV 
non-invasive evaluation of coronary flow reserve (CFR) was performed with 
transthoracic Doppler echocardiography (TDE-CFR). In paper I we measured 
CFR in all three coronary arteries, i.e. left anterior descending artery (LAD), 
left circumflex artery (LCX) and right coronary artery (RCA) while in paper 
IV CFR-measurements were restricted to LAD only. In short, mean diastolic 
flow velocity at baseline and during peak hyperemia, induced by intravenous 
adenosine 140 µgram/kg/min, was measured by manual tracing of the diastolic 
Doppler flow signals. CFR was calculated as the ratio between the hyperemic 
and baseline flow velocity values.  
 
Figure 9. Coronary flow velocity reserve measured with transthoracic Doppler echocardiography. 
Calculated as mean diastolic flow velocity at hyperemia divided by mean diastolic velocity at rest 
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Paper I 
The study population consisted of patients referred to Sahlgrenska University 
Hospital in Gothenburg for evaluation with single photon emission 
tomography (SPECT) due to symptoms of chest pain. Coronary flow velocity 
reserve, defined as coronary flow velocity at hyperemia induced by 
intravenous adenosine, divided by coronary flow velocity at rest, was 
measured in the left anterior descending artery (LAD), circumflex artery (CX) 
and in the right circumflex artery (RCX) with transthoracic Doppler 
echocardiography. Coronary angiography was performed on clinical grounds 
within 180 days before or after measurements of CFR. Data on patient 
characteristics and angiographic findings were collected from SCAAR, patient 
charts and from individual angiograms. Significant CAD was defined as a 
lumen obstruction of >50%.  
To examine if CFR can predict the prevalence of significant coronary artery 
stenosis on coronary angiogram, we used propensity score adjusted 
multivariable logistic regression for the primary analysis. Missing data were 
imputed using the multiple imputation chain-equation method with 20 data 
sets. Several secondary analyses were used to adjust for differences in patient 
characteristics and for sensitivity analysis. 
Paper II 
Patients undergoing PCI due to STEMI and registered in SCAAR during the 
period January 2005 to September 2014, were included. Data from SCAAR 
were merged with the National Patient Registry. Patients were divided into two 
groups; patients undergoing primary PCI plus thrombus aspiration and patients 
undergoing primary PCI alone. 
The primary endpoint was mortality at 30 days. The secondary endpoints were 
mortality at one year, stent thrombosis at 30 days and at one year, and reported 
in-hospital neurological complication. Stent thrombosis was defined as an 
acute stent occlusion verified by coronary angiography. Neurological 
complication was defined as a new neurological deficit during PCI or during 
in-hospital stay after primary PCI. 
Missing data were imputed using the multiple imputation chain-equation 
method with 20 data sets. Instrumental variable 2SLS regression with 6 
administrative health care regions in Sweden based on geographic location as 
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the treatment-preference instrument was used in our primary model. For 
sensitivity analysis a treatment-preference instrument was created by dividing 
hospitals into quintiles based on total number of procedures with thrombus 
aspiration. Our secondary models were based on unadjusted and propensity 
score-adjusted multilevel logistic regression. Administrative healthcare 
regions and individual hospitals were entered into the regression model as 
random-effects variables since SCAAR is a hierarchical database with 
clustering of patients within hospitals and regions. 
Paper III 
Consecutive STEMI-patients who underwent primary PCI (PPCI) in Sweden 
between January 1th 2005 and November 1th 2016 were included in the study. 
Patients were stratified by whether or not they were pretreated with P2Y12 
antagonists. Demographic and procedural data were based on SCAAR-data 
and diagnosis according to International Classification of Diseases codes. Vital 
status and date of death were obtained from the Swedish National Population 
Registry. SCAAR was merged with the Swedish National Population Registry 
by the Epidemiologic Center of the Swedish National Board of Health and 
Welfare according to Swedish personal identification numbers. 
The primary endpoint was all-cause death within 30 days. Secondary endpoints 
were IRA (infarct-related artery) occlusion, stent thrombosis at 30 days, in-
hospital bleeding, neurological complications and cardiogenic shock during 
the index hospitalization. 
Missing data were imputed with the multiple imputation chain-equation 
method with 5 data sets. Associations between P2Y12 pretreatment and the risk 
of adverse outcomes were investigated with propensity-scores adjusted mixed-
effects logistic regression which takes into account clustering of patients 
within hospitals. 
Paper IV 
Patients with previous type-1 myocardial infarction (MI) with at least one 
additional cardiovascular risk factor; age ≥65 years, angiographic evidence of 
multi-vessel coronary artery disease, diabetes mellitus, hypertension, two or 
more spontaneous MIs, chronic, non-end-stage renal dysfunction, incomplete 
revascularization, were included. SCAAR was used to screen patients. 
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Demographic data were collected from SCAAR and from personal visit at the 
time of CFR-evaluation. CFR in LAD was evaluated non-invasively with 
transthoracic Doppler echocardiography. Multiple linear regression was used 
to assess predictors of CFR with the following covariates entered into the 
model; age, gender, BMI, smoking history, hypertension, diabetes mellitus, 
hyperlipidemia, renal dysfunction, chronic obstructive pulmonary disease 
(COPD), peripheral artery disease(PAD), previous stroke, months after MI, 
additional MI, multi-vessel disease, incomplete revascularization, previous 
PCI, previous CABG, angina pectoris and NYHA-class. 
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RESULTS 
Paper I 
152 patients were included in the study. 38.8% had not significant obstructive 
CAD on coronary angiogram, 32.9% had singel-vessel disease and 28.3% had 
multi-vessel disease.  
In the primary model, with propensity score adjusted multivariable logistic 
regression, we found that CFR in LAD (adjusted OR 0.61; 95% CI 0.40-0.92, 
p=0.018), LCX (OR 0.40; 95% CI 0.23-0.71, p=0.002) and RCA (OR 0.38; 
95% CI 0.21-0.72) were independent predictors of significant coronary artery 
disease. These findings consisted in the secondary models with logistic 
regression with complete-case analysis as well as after imputation of missing 
data. Sensitivity analysis based on logistic regression with imputation of 
missing data on patients who had CFR-measurements performed prior to 
coronary angiogram (N=90), and on patients without previous MI, were also 
congruent with the results from the primary model. CFR measured in any of 
the three coronary arteries predicted significant epicardial stenosis 
independently of the location of the stenosis. There was also a significant 
correlation between CFR-values from the three different coronary arteries that 
was independent of stenosis location. In a test for trend CFR was found to 
decrease significantly with increasing severity of CAD. Definition of severity 
of CAD was number of arteries with significant stenosis.  
Paper II 
42 829 consecutive STEMI-patients were included in the study. 29% of these 
were female. 10660 patients (26% female) were treated with thrombus 
aspiration. The frequency of thrombus aspiration in the six healthcare regions 
varied from 18% to 35%. During the study period there was a significant 
decrease in age-and sex-adjusted 30-days mortality as well as in 1-year 
mortality with no difference between men and women. Mortality at 30 days 
was 6.1% in the thrombus aspiration group and 6.3% in the PCI-alone group 
and at 1 year 9.2% and 9.8% respectively.   
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In our primary analysis, with 2SLS regression with administrative health care 
region as treatment preference variable, there was no difference between 
groups neither in 30-day mortality nor in 1-year mortality. The incidence of 
stent thrombosis at 30-days in all patients was 0.6%, in the thrombus aspiration 
group 0.47% and in the PCI-alone group 0,67%. In the primary analysis a 
significant difference both at 30 days and at 1 year was found but in the 
landmark analysis after 30 days there was no difference between groups. In 
hospital-stroke or neurological complications did not differ between groups. 
Paper III 
44804 consecutive STEMI-patients were included after exclusion of patients 
who did not receive acetylsalicylic acid before PCI, patients treated with 
thrombolysis and patients without Swedish identification numbers. 37840 
(84.5%) were pretreated with clopidogrel (N=21642, 57.2%), ticagrelor 
(N=14008, 35.3%) or prasugrel (N=2190, 5.8%). 30387 (67,8%) had an IRA-
occlusion. Patients were reported from 30 different hospitals. The two groups, 
pretreated versus not pretreated, were well balanced after adjustment with 
propensity score.  
At 30 days there was 2488 (5.6%) deaths and 267(0.6%) in stent-thrombosis.  
The primary analysis with propensity-scores adjusted mixed-effects logistic 
regression, showed no difference between groups in 30-days mortality 
(adjusted OR 1.07; 95% CI 0.94-1.22, p=0.313), reduced IRA occlusion 
(adjusted OR 1.01; 95% CI 0,95-1.08; P=0.635), in stent-thrombosis (adjusted 
OR 0.99; 95% CI 0.69-1.41, p=0.941), in-hospital bleeding (adjusted OR 1.04; 
95% CI 0.89-1.23 p=0.604) or neurological complications (adjusted OR 0.66; 
95% CI 0.38-1.30, p=0.129). IRA-occlusion was an independent predictor of 
30-day mortality (adjusted OR 1.65; 95% CI 1.48-1.85) 
Paper IV 
Between July 12th 2013 and December 16th 2015 619 patients were included in 
the study. Median age was 69.0 years (IQR 64.9-73.3) and 18.4 % were female. 
Almost one half of the study population (46.0%) had multi-vessel disease and 
approximately a quarter (23.7%) was incompletely revascularized. The 
majority of patients were free from symptoms of angina and in NYHA class I. 
The major part was also on optimal pharmacological standard treatment. The 
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success-rate for evaluation of CFR in LAD was 98.7% (611 patients). Mean 
CFR was 2.74 (±0.79).  
A large proportion of patients had CFR<2.5 and almost two thirds had 
CFR<3.0. Independent predictors of CFR were age, dyslipidemia, smoking, 
hypertension, body mass index, incomplete revascularization and treatment 
with angiotensin receptor blockers in the multiple linear regression model.  
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DISCUSSION 
The main findings of this thesis are as follows.  
I. CFR measured with transthoracic Doppler echocardiography is an 
independent predictor of significant epicardial coronary artery disease.  
II. CFR is impaired in a large proportion of patients with high-risk individuals 
with previous myocardial infarction despite the implementation of the 
contemporary standard secondary preventive measures.  
III. The observational studies based on the SCAAR registry provide external 
validity for the results from recent randomized trials in which neither thrombus 
aspiration nor pre-treatment with P2Y12-inhibitors was shown to improve 
prognosis in patients undergoing PCI due to STEMI. 
Coronary flow reserve 
In paper I we showed that CFR is an independent predictor of significant 
stenosis on coronary angiogram. Notably, CFR was not only predictive of 
significant stenosis in the measured artery. Instead, we found that CFR 
measured in any of the three coronary arteries predicted significant CAD 
independently of anatomical localization and number of diseased arteries. We 
also demonstrated a significant correlation between CFR measured in LAD, 
LCX and RCA respectively, and this was independent of location of lesions. 
This is well in line with the current view of coronary artery disease (CAD) as 
a systemic and progressive immuno-inflammatory disease affecting the overall 
coronary circulation, epicardial as well as microvascular parts. Endothelial 
dysfunction, and as a consequence microvascular dysfunction, is known to 
precede the development of atherosclerotic disease22 and the functionality of 
coronary circulation can be seen as a marker of the pro-atherosclerotic 
properties of the circulatory system.  When CAD eventually manifests with a 
significant stenosis this is preceded by a disturbance in coronary microvascular 
function that is not only located at the site of the stenosis, it is a generalized 
condition engaging the entire coronary circulation. Impaired CFR is proven to 
be associated with greater plaque burden and a higher prevalence of vulnerable 
plaques as well as with higher levels of high-sensitivity C-reactive protein, 
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which indicates an ongoing pro-thrombotic and pro-inflammatory process148. 
We also demonstrated that CFR decreased with increasing severity of coronary 
artery disease. CFR reflects the combined effects of coronary microvascular 
function, flow-limiting epicardial disease as well as rheological properties of 
blood and probably other unknown factors involved in regulation of blood 
flow, and can be used as an indicator of the severity of atherosclerotic disease. 
Indeed, an inverse dose-response relationship between CFR and prognosis has 
recently been proven by our group as well as by others67, 95.  
In paper IV we found impaired CFR in an unexpectedly large proportion of 
patients with a history of myocardial infarction and with at least one additional 
cardiovascular risk factor. This was despite the fact that the majority of patients 
were free from symptoms of angina, in NYHA-class I and on optimal 
secondary preventive therapy. The strongest independent predictor of CFR was 
incomplete revascularization. This confirms the findings in recent studies 
demonstrating the importance of complete revascularization56. However, in our 
study 69% of patients with CFR<2.5 were completely revascularized at the 
time of the index procedure. In patients without obstructive epicardial disease 
decreased CFR is associated with increased risk of mortality reflecting the 
prognostic impact of microvascular dysfunction67, 94.  Successful treatment of 
conventional cardiovascular risk factors improves CFR but apparently this is 
not enough in a substantial number of high-risk individuals. CFR contains 
information additive to known cardiovascular risk factors and could be useful 
in identifying those at extra high-risk in order to individualize targeted 
treatment and reduce major adverse cardiovascular events.  
The success rate in evaluating CFR with transthoracic Doppler technique was 
high in both paper I and in paper IV. In paper I CFR was measured in all three 
coronary arteries, e.g. left anterior descending artery, (LAD), left circumflex 
artery (LCX) and right coronary artery (RCA). CFR from a single artery was 
equally predictive as the average value from all three arteries. As a 
consequence, it is reasonable to restrict the examination to LAD since this is 
technically easier, takes less time and makes it more tolerable to the patient. 
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Thrombus aspiration in STEMI 
In paper II we found that treatment with thrombus aspiration was not 
associated with decreased risk of mortality and in-hospital stroke or neurologic 
complications and that thrombus aspiration was associated with decreased risk 
of stent thrombosis. These results are in agreement with the results from two 
recent large randomized controlled trials, TASTE and TOTAL, and provides 
important evidence for the external validity of these 2 trials. Our data are 
derived from SCAAR and all consecutive STEMI patients in Sweden over a 
period of 9 years, representing unselected patients from everyday practice. 
Important criticism of both TASTE and TOTAL is the presence of selection 
bias resulting in limited external validity, a common problem with RCTs. We 
used treatment preference instrumental variable analysis with 2SLS regression. 
This method allows for adjustment of both measured and unmeasured 
confounders. Observational studies based on instrumental variable method 
mimic the act of randomization in RCT conditional on some central 
methodological assumptions (i.e. a valid instrument reflecting a naturally 
occurring randomization process). Stent thrombosis is a feared complication 
during and after PCI as it is associated with high mortality149. In our study 
thrombus aspiration was associated with decreased risk of stent thrombosis at 
30 days but not at 1 year. This finding is consistent with the results of TASTE 
regarding short- and long-term risk of stent thrombosis and supports the 
evidence for a protective role of thrombus aspiration against acute and 
subacute stent thrombosis. Similar to TASTE but in contrast to TOTAL, we 
did not show an increased risk of stroke or neurological complications 
associated with thrombus aspiration. This could be explained by the low 
number of events in TOTAL, limiting the statistical power. 
Pretreatment in STEMI 
At present time, pre-hospital administration of P2Y12 inhibitors is a common 
practice despite the lack of definite evidence for its benefit. This is reflected in 
paper III where more than 80% of 44804 patients undergoing PCI for STEMI 
in Sweden between January 2005 and November 2016, received prehospital 
P2Y12. The ATLANTIC trial is the only larger randomized trial on pre-
treatment versus in-hospital treatment with P2Y12 inhibitors in patients 
undergoing PCI due to STEMI. In ATLANTIC there was no difference 
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between groups in the composite primary endpoint of ST-segment elevation 
resolution >70% and TIMI flow III. Similarly, there was no difference in death, 
myocardial infarction, stroke, urgent revascularization, definite or probable 
stent thrombosis, patency of infarct related artery or the need for bailout with 
GP2b/3a receptor antagonists133. Consistent with the findings in the smaller 
ATLANTIC, we could not demonstrate an association between prehospital 
P2Y12 -administration and improved survival or higher likelihood of patent 
infarct related artery, neither a lower risk of stent thrombosis or stroke.  
Our large observational study provides evidence for external validity of the 
smaller ATLANTIC trial. However, the debate about the reason for the lack of 
beneficial effect of pre-hospital P2Y12 treatment continues. Some clinicians 
and scientists argue that the difference in time of platelet inhibition in the 
setting of relatively short reperfusion times in STEMI is simply not long 
enough to create meaningful differences in clinical outcome. Others argue that 
impaired gastrointestinal perfusion due to hemodynamic instability or nausea 
and vomiting, as well as administration of morphine, could cause delayed 
absorption of oral P2Y12 antagonists. However, our findings are also consistent 
with the explanation that pretreatment with P2Y12 antagonists in the presence 
of other prehospital pharmacological interventions (ASA and unfractionated 
heparin/low-molecular weight heparin) is simply futile. The possibility that 
pretreatment is futile is directly supported by the results from the ACCOAST 
trial. ACCOAST trial studied early vs late P2Y12 receptor inhibition with 
prasugrel in patients with non-STEMI and showed no difference in major 
adverse cardiovascular events but an increased risk of major bleeding. In the 
prespecified substudy of ACCOAST trial, the authors evaluated the effect of 
administration of prasugrel before coronary angiography versus administration 
at the time for decision to perform PCI. Administration of prasugrel before 
angiography substantially decreased platelet reactivity at the time of 
angiography down to 15% of the platelet reactivity measured in patients who 
were not pretreated. Still, no reduction in the rate of major ischemic events up 
to 30 days in the pretreated group could be demonstrated. We argue that 
upstream treatment with P2Y12 receptor antagonists in STEMI should be 
avoided due to the following reasons. First, no study has convincingly 
demonstrated superiority with upstream P2Y12 antagonists whereas some 
studies have shown harm with increased risk of major bleeding.  Second, 
excess early mortality was observed among patients who were treated with 
upstream ticagrelor in the ATLANTIC trial.  Third, inadvertent treatment of 
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patients who fulfill the criteria for absolute contraindication (e.g. patients with 
aortic dissection/rupture, intra-abdominal bleeding, subarachnoid hemorrhage) 
for antiplatelet therapy may result in catastrophic consequences. Inadvertent 
treatment is particularly problematic in the context of everyday clinical 
practice as opposite to clinical trials in which indication for initiation of the 
treatment are usually more thoroughly scrutinized. We argue that in the 
absence of convincing evidence for a beneficial effect among patients with 
acute coronary syndromes, accidental upstream administration of a P2Y12 
antagonist to any patient with absolute contraindication is inexcusable. 
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CONCLUSIONS 
Paper I:  
CFR evaluated with transthoracic doppler echocardiography is predictive of 
significant coronary artery disease in any of the three coronary arteries.  
Paper II:  
There was no effect of thrombus aspiration on mortality in this population of 
45515 STEMI-patients from the prospective SCAAR database. This study 
gives external validity to the previous large randomized trials; TOTAL and 
TASTE. We found that thrombus aspiration may reduce the risk of stent 
thrombosis but future studies should evaluate if this treatment is cost-effective 
for prevention of stent thrombosis in the absence of survival benefit. 
Paper III:  
Pretreatment with P2Y12-inhibitors in patients undergoing PCI due to STEMI 
is not associated with less mortality, patent IRA, reduced risk of stent-
thrombosis, increased risk of in-hospital bleeding or on-hospital neurological 
complications. 
Paper IV:  
A majority of patients with previous MI and additional risk factors have 
decreased CFR despite adequate secondary preventive intervention. 
Incomplete revascularization is the strongest independent predictor of CFR. 
CFR is a valuable prognostic tool in stratification of high-risk populations with 
previous MI. 
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FUTURE PERSPECTIVES 
In the clinical setting 
CFR could be used for screening and risk stratifying of both asymptomatic 
high risk individuals as well as of those with symptoms suggestive of coronary 
artery disease. CFR could be valuable in individualizing therapies, both 
interventional and pharmacological, on top of established treatment of 
coronary artery disease. 
CFR-measurements could be implemented in routine echocardiographic 
procedures, both in outdoor clinic and in the ward, since the procedure is easy 
to perform for clinicians familiar with echocardiography, and it is an easy 
accessible and patient friendly method associated with low costs. 
In the acute setting interpretation of CFR can be hazardous as it is sensitive to 
variations in basal flow velocities but in the catheter laboratory the 
examination can be complemented by assessment of FFR and IMR which are 
independent of hemodynamic parameters such as blood pressure, heart rate and 
basal flow. 
In general science 
CFR could be used as a valid surrogate end-point in interventional studies 
evaluating the effects of pharmacological and other interventions on 
cardiovascular morbidity and mortality. 
High-quality national registries are valuable tools in research and with 
adequate statistical modelling they serve as an important complement to 
randomized trials in providing external validity. Recently, the new concept of 
registry-based randomized controlled trials (RRCT) has evolved where 
patients are assigned to a treatment through randomization in a clinical 
registry. This kind of registry-based trials renders large cohorts in a short time. 
Data on both included subjects as well as those not included will be complete 
and costs are low. 
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